Get access to the event platform




Brigitte Bruijns received her bachelor degree in Advanced Technology (University of Twente) in 2007. After that she graduated in 2008 and 2010 for respectively Science Education – Chemistry (University of Twente) and Forensic Science (University of Amsterdam) for which she carried out part of her research project at the University of Canberra, Australia. As part of her masters in Analytical Sciences (University of Amsterdam), for which she graduated in 2011, she did her research project in the group of prof. Gardeniers. The project was entitled “Illicit drugs analysis on chip” and had as goal to develop a microfluidic device for a forensic application. She received her PhD in Jan 2019 and works currently as R&D Scientist at Micronit Microtechnologies.




In 1999, Ronny van ’t Oever co-founded Micronit Microfluidics, currently known as Micronit Microtechnologies. Since 2011, he serves as Chief Executive Officer for this company. Prior to starting Micronit, Ronny began his career at the Abbott Diagnostics Division in Santa Clara, California. With a passion to bring innovative products to the market, Ronny recognizes the need to connect government, research institutes and industry. Therefore, he currently holds the position of President of MinacNed, a Dutch trade association aiming to strengthen the economic activity based on microsystems and nanotechnology. Ronny van ’t Oever graduated with a master’s degree in Physics at the University of Twente in Enschede. In 2007, he was awarded ‘Engineer of the year’ in the Netherlands.


How a crisis leads to collaboration

Shortly after the first COVID infections in the Netherlands the Viralert initiative was born. Within this initiative multiple collaborations and consortia were created leading to various strategies to coop with the crisis. One of these collaborations is the VIRAPOC project, where 5 MKB partners from the (East part of) the Netherlands are collaborating to develop a point of care system. First focus is a fast test (< 30 min) for SARS-CoV-2, but the generic platform is suitable for different assays. With this development we would like to bring the lab to the patient!

Announced soon